In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature

Nature Protocols

Volumn 1, Issue 1, 2006, Pages 192-199

  Roesli, Christoph ^a   Neri, Dario ^a   Rybak, Jascha N ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; PLASMA PROTEIN; TUMOR ANTIGEN;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BIOTINYLATION; BLOOD; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOUSE; PERFUSION; PROTEOMICS;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIOTINYLATION; BLOOD PROTEINS; MICE; ORGAN SPECIFICITY; PERFUSION; PROTEOMICS;

EID: 34250664284     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2006.29     Document Type: Article

References (27)

1. Neri, D. & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5, 436-446 (2005).
2. Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275 547-550 (1997).
3. Wu, A.M. & Senter, P.D. Arming antibodies: Prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (2005).
4. Adams, G.P. & Weiner, L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005).
5. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001).
6. Winter, G., Griffiths, A.D., Hawkins, R.E. & Hoogenboom, H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12 433-455 (1994).
7. Silacci, M. et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5, 2340-2350 (2005).
8. Collins, J., Horn, N., Wadenback, J. & Szardenings, M. Cosmix-plexing: A novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74, 317-338 (2001).
9. Brody, E.N. & Gold, L. Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74, 5-13 (2000).
10. Erlanson, D.A. et al. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 21, 308-314 (2003).
11. Melkko, S., Scheuermann, J., Dumelin, C.E. & Neri, D. Encoded self-assembling chemical libraries. Nat. Biotechnol. 22, 568-574 (2004).
12. Shuker, S.B., Hajduk, P.J., Meadows, R.P. & Fesik, S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
13. St. Croix, B. et al. Genes expressed in human tumor endothelium. Science 289, 1197-1202 (2000).
14. Huminiecki, L. & Bicknell, R. In silico cloning of novel endothelial-specific genes. Genome Res. 10, 1796-1806 (2000).
15. Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366 (1996).
16. Arap, W., Pasqualini, R. & Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380 (1998).
17. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635 (2004).
18. Rybak, J.N. et al. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2, 291-298 (2005).
19. Rybak, J.N., Scheurer, S.B., Neri, D. & Elia, G. Purification of biotinylated proteins on streptavidin resin: A protocol for quantitative elution. Proteomics 4, 2296-2299 (2004).
20. Zardi, L. et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 6, 2337-2342 (1987).
21. Pini, A. et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21776 (1998).
22. Castellani, P. et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am. J. Pathol. 161, 1695-1700 (2002).
23. Borsi, L. et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75-85 (2002).
24. Berndorff, D. et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate. Clin. Cancer Res. 11, 7053s-7063s (2005).
25. Carnemolla, B. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665 (2002).
26. Ebbinghaus, C. et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116, 304-313 (2005).
27. Menrad, A. & Menssen, H.D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9 491-500 (2005).